Horizon Therapeutics (United States)

Recent papers from Horizon Therapeutics (United States)

1. Evaluation of two novel effectorless immunoPET agents for tracking human CD19-positive B lymphocytes in experimental autoimmune encephalomyelitisJournal of Neuroinflammation · 2026
2. Dual costimulation blockade with the CD154-specific fusion protein dazodalibep and belatacept for prophylaxis of kidney allograft rejectionAmerican Journal of Transplantation · 2026
3. A pharmacokinetics study to evaluate drug–drug interactions between fipaxalparant and concomitant medications in healthy participantsClinical Pharmacology in Drug Development · 2025
4. Urban Care Farming to Enhance Quality of Life Among Older Adults: Protocol for a Waitlist Randomized TrialJMIR Research Protocols · 2025
5. A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraineHeadache The Journal of Head and Face Pain · 2025
6. A next-generation HDAC6 inhibitor for amyotrophic lateral sclerosis and frontotemporal dementiaBrain · 2025
7. Development and preclinical characterization of AMG 329: a human antibody neutralizing FLT3 ligandmAbs · 2025
8. Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network DatabaseRheumatology and Therapy · 2025
9. Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trialFrontiers in Immunology · 2025
10. Integrated SegFlow, µSIA, and UPLC for Online Sialic Acid Quantitation of Glycoproteins Directly from BioreactorsEngineering in Life Sciences · 2025
11. Pegloticase and Methotrexate Cotherapy in Patients With Uncontrolled Gout With Prior Pegloticase Monotherapy Failure: Findings of an Open‐Label TrialACR Open Rheumatology · 2025
12. Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims AnalysisRheumatology and Therapy · 2024
13. Pegloticase-Induced Rapid Uric Acid Lowering and Kidney and Cardiac Health Markers in Youth-Onset Type 2 Diabetes: A Pilot Clinical TrialKidney Medicine · 2024
14. B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activityAnnals of Clinical and Translational Neurology · 2024
15. Antiseizure Medication Withdrawal, Risk of Epilepsy, and Longterm EEG Trends in Acute Symptomatic Seizures or Epileptic EEG PatternsNeurology Clinical Practice · 2024
16. Op0058 Dazodalibep (Anti-Cd40l) Effectively Reduces Multiple Proteins Associated With B-, T-, and Dendritic Cell Biomarkers in Sjӧgren’s Disease: Corroboration of Immunophenotyping Findings From the Aliss Phase 2 StudyAnnals of the Rheumatic Diseases · 2024
17. Ab0746 Cd40l Blockade With Dazodalibep Significantly Improves Disease Activity, Swollen and Tender Joint Counts, While Reducing Multiple T- And B-Cell Biomarkers in the Midora Phase 2 Study of Patients With Moderate-to-Severe Active Rheumatoid ArthritisAnnals of the Rheumatic Diseases · 2024
18. Ab0815 Global Burden of Sjogren’s Disease (Sjd): Findings From a Systematic Literature Review (Slr) of Humanistic and Clinical OutcomesAnnals of the Rheumatic Diseases · 2024
19. Ab0793 the Use of Natural Language Processing to Characterize Disease Burden: Sexual Distress in Sjögren’s DiseaseAnnals of the Rheumatic Diseases · 2024
20. Ab0794 Using Social Media Listening to Characterize the Flare Lexicon in Patients With Sjögren’s DiseaseAnnals of the Rheumatic Diseases · 2024